It is worth stating plainly that this lean subgroup is exactly where the read-across from obesity, diabetes, and MASLD data is weakest: those trials enrolled few, if any, participants resembling a normal-weight woman with androgen-driven, intrinsic insulin resistance, so the confidence interval around any predicted effect in her is wide and honestly unknowable from the current evidence
N Engl J Med 377:644657 Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes
Additionally, theres just not enough research out there to confirm that these natural GLP-1 alternatives will help you lose weight
Holst also synthesised a peptide based on the newly discovered gene sequence for GLP-1 reported by Bell
- ERRgamma (ESRRG) : skeletal muscle, myocardium, brain, adult liver
This innovative medication contains semaglutide , a GLP-1 receptor agonist that effectively reduces appetite and slows digestion to promote weight loss
